Salix's TARGET 3 study examines the safety and efficacy of repeat treatment with Rifaximin for IBS with diarrhea

Salix Pharmaceuticals, Ltd. has announced that Dr. Anthony Lembo of Beth Israel Deaconess Medical Center will present the results of TARGET 3 in a late-breaking podium presentation at the...